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http://dx.doi.org/10.1016/j.stemcr.2016.05.003SUMMARYMesenchymal stromal cells (MSCs) are promising therapeutic candidates given their potent immunomodulatory and anti-inflammatory
secretome. However, controlling the MSC secretome post-transplantation is considered a major challenge that hinders their clinical
efficacy. To address this, we used a microparticle-based engineering approach to non-genetically modulate pro-inflammatory pathways
in human MSCs (hMSCs) under simulated inflammatory conditions. Here we show that microparticles loaded with TPCA-1, a small-
molecule NF-kB inhibitor, when delivered to hMSCs can attenuate secretion of pro-inflammatory factors for at least 6 days in vitro.
Conditionedmedium (CM) derived fromTPCA-1-loaded hMSCs also showed reduced ability to attract humanmonocytes and prevented
differentiation of human cardiac fibroblasts to myofibroblasts, compared with CM from untreated or TPCA-1-preconditioned hMSCs.
Thus, we provide a broadly applicable bioengineering solution to facilitate intracellular sustained release of agents that modulate
signaling. We propose that this approach could be harnessed to improve control over MSC secretome post-transplantation, especially
to prevent adverse remodeling post-myocardial infarction.INTRODUCTION
Mesenchymal stromal cells (MSCs; also known as bone
marrow stromal cells and earlier known as mesenchymal
stem cells) are being explored as therapeutics in over 550
clinical trials registered with the US Food and Drug Admin-
istration (www.FDA.gov) for the treatment of a wide
range of diseases (Ankrum et al., 2014c). Their immune-
evasive properties (Ankrum et al., 2014c) and safe trans-
plant record, allowing allogeneic administration without
an immunosuppressive regimen, positions MSCs as an
appealing candidate for a potential off-the-shelf product.
One of the primary mechanisms exploited in MSC thera-
peutics is a secretome-based paracrine effect as evidenced
in many pre-clinical studies (Ranganath et al., 2012). How-
ever, controlling the MSC secretome post-transplantation
is considered a major challenge that hinders their clinical
efficacy. For instance, upon transplantation, MSCs are sub-
jected to a complex inflammatory milieu (soluble media-
tors and immune cells) in most injury settings. MSCs not
only secrete anti-inflammatory factors, but also produce
pro-inflammatory factors that may compromise their ther-
apeutic efficacy. Table S1 lists a few in vitro and in vivo con-
ditions that demonstrate the complex microenvironment
under which MSCs switch between anti-inflammatory
and pro-inflammatory phenotypes.
Levels of pro- or anti-inflammatory cytokines are not
always predictive of the response, possibly due to the926 Stem Cell Reports j Vol. 6 j 926–939 j June 14, 2016 j ª 2016 The Autho
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sent in the cell microenvironment (Table S1). For example,
relatively low inflammatory stimulus (<20 ng/ml tumor ne-
crosis factor alpha [TNF-a] alone or along with interferon-g
[IFN-g]) can polarize MSCs toward pro-inflammatory ef-
fects (Bernardo and Fibbe, 2013) resulting in increased
inflammation characterized by T cell proliferation and
transplant rejection. Conversely, exposure to high levels
of the inflammatory cytokine TNF-a has been shown in
certain studies to result in MSC-mediated anti-inflamma-
tory effects via secretion of potent mediators such as
TSG6, PGE2, STC-1, IL-1Ra, and sTNFR1 as demonstrated in
multiple inflammation-associated disease models (Prockop
and Oh, 2012; Ylostalo et al., 2012). These effects are medi-
ated via molecular pathways such as NF-kB, PI3K, Akt, and
JAK-STAT (Ranganath et al., 2012). However, it is not clear
that low and high levels of TNF-a always exert the same
effect on anti- versus pro-inflammatory MSC secretome.
NF-kB is a central regulator of the anti-inflammatory secre-
tome response in monolayer (Yagi et al., 2010), spheroid
MSCs (Bartosh et al., 2013; Ylostalo et al., 2012) and TNF-
a-mediated (20 ng/ml for 120 min) apoptosis (Peng et al.,
2011). Given that NF-kB can promote secretion of pro-
inflammatory components in the MSC secretome (Lee
et al., 2010), we hypothesized that NF-kB inhibition via
small molecules in MSC subjected to a representative in-
flammatory stimulus (10 ng/ml TNF-a) would inhibit their
pro-inflammatory responses.rs.
ecommons.org/licenses/by-nc-nd/4.0/).
Adverse remodeling or cardiac fibrosis due to differentia-
tion of cardiac fibroblasts (CF) into cardiac myofibroblasts
(CMF) with pro-inflammatory phenotype and collagen
deposition is the leading cause for heart failure. The secre-
tome from exogenous MSCs has anti-fibrotic and angio-
genic effects that can reduce scar formation (Preda et al.,
2014) and improve ejection fraction when administered
early or prior to adverse remodeling (Preda et al., 2014;
Tang et al., 2010; Williams et al., 2013). Unfortunately in
many cases, due to poor prognosis, MSCs may not be
administered in time to prevent adverse remodeling to
inhibit CF differentiation to CMF (Virag and Murry,
2003) or to prevent myocardial expression of TNF-a (Boz-
kurt et al., 1998; Mann, 2001). Also, when administered
following an adverse remodeling event including CMF
differentiation, MSCs may assume a pro-inflammatory
phenotype and secretome (Naftali-Shani et al., 2013) under
TNF-a (typically 5 pg/mg of total protein in myocardial
infarction (MI) rat myocardium which is not significantly
higher than 1–3 pg/mg protein in control rat myocardium)
(Moro et al., 2007) resulting in impaired heart function.
Hence, if the pro-inflammatory response of hMSCs can
be suppressed it may maximize efficacy.
While theMSC phenotype can be controlled under regu-
lated conditions in vitro, the in vivo response of MSCs
post-transplantation is poorly controlled as it is dictated
by highly dynamic and complex host microenvironments
(Discher et al., 2009; Rodrigues et al., 2010). Factors
including MSC tissue source (Melief et al., 2013; Naftali-
Shani et al., 2013), donor and batch-to-batch variability
with respect to cytokine secretion and response to inflam-
matory stimuli (Zhukareva et al., 2010), gender (Crisos-
tomo et al., 2007), and age (Liang et al., 2013) also affect
the response of MSCs. Thus, it is important to develop
approaches to control the MSC secretome post-transplan-
tation regardless of their source or expansion conditions.
We hypothesized that engineering MSCs to induce a
specific secretome profile under a simulated host microen-
vironment may maximize their therapeutic utility. Previ-
ously, the MSC secretome has been regulated via genetic
engineering (Gnecchi et al., 2006; Wang et al., 2009)
or cytokine/small-molecule preconditioning approaches
(Crisostomo et al., 2008; Mias et al., 2008). Genetically
engineered human MSCs (hMSCs) pose challenging
long-term regulatory hurdles given that the potential
tumorigenicity has not been well characterized, and while
preconditioning hMSCs with cytokines/small molecules
may be safer, the phenotype-altering effects are transient.
In this study, we aimed tomodulate the hMSC secretome
with a small molecule, specifically inhibiting the pro-in-
flammatory components while maintaining few anti-in-
flammatory and angiogenic components. Through this
strategy, we sought to minimize CMF differentiation andinhibit total collagen deposition, which are primary
mediators of cardiac fibrosis. Using TNF-a stimulated
NF-kB activation as a model of inflammation, we show
that microparticle-mediated continuous delivery of an
NF-kB inhibitor can provide sustained inhibition of the
hMSC pro-inflammatory secretome and thereby inhibit
monocyte migration, CMF differentiation, and collagen
deposition.RESULTS
Profiling the hMSC Secretome upon TNF-a
Stimulation
To identify relevant targets for inhibition of the pro-inflam-
matory secretome, we profiled hMSCs treated with the
pro-inflammatory stimulus TNF-a by quantifying over 250
cytokines and chemokines in the hMSC conditioned me-
dium (CM) using antibody arrays (Figure 1A). See Table 1
for details of the experimental groups. Upon TNF-a stimula-
tion, there was notable increase in the secretion of multiple
cytokines and chemokines in the CM compared with con-
trol-hMSCs (Figure1B).While constitutively secretedpro-in-
flammatory cytokines IL-6, IL-8,MCP-1, andMCP-3 showed
modest increase (19-, 5-, 2.6-, and 4-fold, respec-
tively), TNF-a stimulation resulted in secretion of pro-in-
flammatory cytokines RANTES (CCL5), ENA78, GRO, and
GCP-2 at significantly elevated concentrations (4,000-,
133-, 17-, and 63-fold, respectively) compared with
control-hMSCs (Figure 1B).TPCA-1 Inhibits Secretion of Pro-inflammatory
Cytokines from TNF-a-Stimulated hMSCs
To investigate whether the increased secretion of pro-in-
flammatory factors upon TNF-a stimulation in hMSCs is
mediated by NF-kB, we used small-molecule inhibitors of
NF-kB, namely PSI (proteasome inhibitor) and TPCA-1
(IKKb inhibitor). PSI was highly toxic to the cells (IC50
3 mM;where IC50 is themedian inhibitory concentration)
when treated for 48 hr (Figure S1A), but at lower concentra-
tion (10 nM) PSI did not inhibit secretion of IL-6, a pro-in-
flammatory cytokine secreted at high levels upon TNF-a
stimulation of hMSCs (Figure S1B). In contrast, TPCA-1
had low toxicity on hMSCs (IC50 90 mM) when treated
for 48 hr (Figure S1C) and 10 mMconcentration was chosen
for future experiments. In addition, TPCA-1 treatment at
10 mM did not inhibit osteogenic and adipogenic differen-
tiation of hMSCs (Figures S2A and S2B).
To test theutilityofTPCA-1asa reversiblemodulatorof the
NF-kB mediated pro-inflammatory secretome, we tested its
effect on cytokine production by TNF-a activated hMSCs.
Control (control-hMSC), TNF-a-treated (TNF-hMSC), and
TNF-a/TPCA-1-treated hMSC (TNF + TPCA-hMSC) wereStem Cell Reports j Vol. 6 j 926–939 j June 14, 2016 927
Figure 1. Characterization of hMSC Pro-
inflammatory Secretome upon TNF-a
Stimulation and TPCA-1 Treatment
(A) Fluorescence images of cytokine anti-
body arrays obtained via laser scanning
microplate reader from multiple hMSC se-
cretome samples.
(B) Concentration profile of hMSC secre-
tome obtained via quantitative analysis of
RayBiotech Quantibody arrays using GenePix
Pro software. Of 250 cytokines, chemokines,
and growth factors profiled, mediators that
were statistically significant among the
three hMSC samples are reported. @ refers
to 1/10th of the actual concentration of
ENA78. $ and NS indicate p < 0.01 and not
significant between secretome from control-
hMSC and TNF-hMSC, respectively; * and NS
indicate p < 0.01 and not significant be-
tween secretome from TNF-hMSC and TNF +
TPCA-hMSC, respectively; # and NS indicate
p < 0.01 and not significant between secre-
tome from control-hMSC and TNF + TPCA-
hMSC, respectively.
(C) Fold change in concentration of hMSC
secretome components normalized to con-
centration of secretome components in TNF-
hMSC. p values indicate significance (*p < 0.01) between secretome from TNF-hMSC and TNF + TPCA-hMSC. Data represent the average of
duplicates from three independent experiments from two donor MSCs. Error bars represent ± SD.incubated for48hr in serum-freemedium.SustainedTPCA-1
treatment in TNF + TPCA-hMSCs significantly reduced the
secreted levels of pro-inflammatory mediators MCP-1,
RANTES, GCP-2, LIF, andMCP-3 to lower than or equivalent
to the basal levels of control-hMSCs (Figure 1B). Secreted
levels of IL-6, IL-8, and GRO were significantly lower than
levels secreted by TNF-hMSCs. In addition, reduction in
cytokine secretion levels for TNF + TPCA-hMSC CM versus
TNF-hMSC CM were as follows: IL-6 (6-fold), IL-8 (1.2-
fold), LIF (9-fold), MCP-1 (7-fold), MCP-3 (3-fold),
RANTES (5,400-fold), ENA78 (45-fold), GRO (6-fold),
and GCP-2 (58-fold) (Figure 1C).
Next, we sought to examine if TPCA-1 would inhibit the
beneficial paracrine effect of hMSCs mediated by several
pathways including JAK-STAT, PI3/Akt, and MAPK (Ranga-
nath et al., 2012). Concentrations of growth factors, cyto-
kines, and anti-inflammatory mediators were quantified
from Quantibody arrays. Secretion of most growth factors
(Figures S3A and S3B) and cytokines (Figures S3C and
S3D) was unaffected even upon TNF-a stimulation and
TPCA-1 treatment, except for HGF-1 the secretion of which
was significantly inhibited upon TPCA-1 treatment (Fig-
ure S3A). However, secretion of platelet-derived growth
factor-AA and anti-inflammatory cytokine TSG-6 was
significantly augmented upon TNF-a stimulation and928 Stem Cell Reports j Vol. 6 j 926–939 j June 14, 2016maintained at elevated levels even upon TPCA-1 treatment
(Figures S3A and S3D).
Functionality of the inhibited pro-inflammatory hMSC
secretome was characterized by investigating transwell
migration of human monocytes in vitro (Figure S4A). Fig-
ure S4B indicates that TPCA-1 treatment significantly
inhibited transwell migration of human monocytes in
response to TNF-hMSC secretome. This, along with the
inhibition of pro-inflammatory secretome by TPCA-1
prompted us to develop a non-genetic, autonomous
controlled release approach for modulating pro-inflamma-
tory secretome in hMSCs.
Surface Modified PLGA Microparticles Delivering
TPCA-1 are Internalized into hMSCs
Previously, we demonstrated a particle-in-cell approach
where 1–2 mm drug-loaded poly(D,L-lactide-co-glycolide)
(PLGA)microparticles were internalized into hMSCs and re-
tained at least for 7 days and potentially weeks (Sarkar et al.,
2011).Drugs released fromtheseparticle-engineeredhMSCs
demonstrated sustained phenotype-altering effects (Ank-
rumet al., 2014a; Sarkar et al., 2011). In this study, we devel-
oped 1–2 mm PLGA microparticles encapsulating TPCA-1
using the single-emulsion solvent evaporation technique.
PLGA with a glycolic acid to lactic acid ratio of 50:50 and
Table 1. Abbreviations and Expanded Forms of the
Experimental Groups
Abbreviations Description of the Experimental Groups
Control-hMSC treated with 1% DMSO for 48 hr
TNF-hMSC treated with 10 ng/ml TNF-a and 1% DMSO for 48 hr
TNF +
TPCA-hMSC
treated with 10 ng/ml TNF-a and 10 mM
TPCA-1 for 48 hr
TPCA-hMSC treated with 10 mM TPCA-1 for 48 hr
TPCApre +
TNF-hMSC
pre-treated with 10 mM TPCA-1 for 24 hr
and after removal of TPCA-1, treated with
10 ng/ml TNF-a every 48 hr
TPCApre-hMSC pre-treated with 10 mM TPCA-1 for 24 hr
mP-hMSC loaded with 200 mg/ml blank microparticles
and incubated for 24 hr
TNF + mP-hMSC loaded with 200 mg/ml blank microparticles,
incubated for 24 hr and treated with 10 ng/ml
TNF-a every 48 hr
TPCAmP-hMSC loaded with 200 mg/ml TPCA-microparticles
and incubated for 24 hr
TNF +
TPCAmP-hMSC
loaded with 200 mg/ml TPCA-microparticles,
incubated for 24 hr and treated with 10 ng/ml
TNF-a every 48 hr10 kDa molecular weight was chosen to formulate the mi-
croparticles to ensure faster degradation. Themicroparticles
were round in shape with smooth surface morphology (Fig-
ure 2A)with a relativelyhomogeneous size distribution (PDI
0.26) (Figure 2B). Given the anionic surface property of
PLGA used in this study, the surface of the microparticles
was negatively charged (Figure 2B). Flow cytometry analysis
of fluorescent dye-loaded microparticles (DmPs) revealed
their association with hMSCs (Figure 2C), and confocal
imaging confirmed that they were only associated with the
cellmembrane andnot completely internalized (Figure 2D).
To ensure internalization, the microparticles were treated
with cationic polymer poly-L-lysine (PLL) resulting in
reduced negative surface charge (Figure 2B). Flow cytometry
analysis confirmed that PLL-coated microparticles had
greater interaction with hMSCs (increase in average fluores-
cent intensity, Figure 2C), and confocal imaging revealed
internalization (Figure 2D). The microparticles were formu-
lated with 19% (w/w) TPCA-1 loading and 80% encapsula-
tion efficiency (Figure 2B), and PLL coating did not affect
these parameters. The microparticles released TPCA-1
completely within 20 days of incubation in PBS at 37C
withanear zero-order releasekinetics (Figure2E).Themicro-
particles degraded almost completely after 20 days suggest-
ing that the drug was encapsulated. Incubation of hMSCs
with TPCAmP concentrations of up to 200 mg/ml for 7 days
did not affect cell viability (Figure S1D).TPCAmPs Sustainably Inhibit Pro-inflammatory
Secretome in TNF-a-Stimulated hMSCs
Next, we compared our microparticle engineering regimen
with the conventional preconditioning regimen to investi-
gate if our approach would provide sustained modulation
of the hMSC secretome under TNF-a stimulation. From
the pro-inflammatory secretome profiled earlier, IL-6,
MCP-1 (CCL2), and RANTES (CCL5) were selected for this
study as they are known to significantlymediate inflamma-
tory responses in many cell types. Soluble TPCA-1 precon-
ditioning (Figure 3A) could inhibit secretion of RANTES
from TNF-hMSC significantly for only 2 days (Figure 3B).
Soluble TPCA-1 preconditioning was unable to inhibit
IL-6 and MCP-1 secretion in TPCApre + TNF-hMSCs (Fig-
ure 3B) throughout the assay. mP-hMSCs displayed a secre-
tory profile similar to control-hMSCs and, upon TNF-a
stimulation, secreted upregulated levels of RANTES, IL-6,
and MCP-1 similar to TNF-hMSCs. Notably, TPCAmP-
hMSCs, upon repeated TNF-a stimulation, displayed signif-
icant inhibition in secreted levels of RANTES (low to basal
level) until 6 days and IL-6 and MCP-1 until 4 days
(Figure 3B).
Intracellular TPCA Released from Microparticles
Inhibits NF-kB Nuclear Translocation in TNF-
a-Stimulated hMSCs
We then sought to examine the effect of TNF-a and TPCA
(exogenous and intracellularly released from microparti-
cles) on NF-kB signaling in hMSCs. The experimental
design is similar to the one depicted in Figure 3A except
that the cells were stained 30 min after TNF-a stimulation
due to the rapid nuclear translocation of NF-kB (p65 sub-
unit). The p65 subunit of NF-kB complex was absent in
the nuclei of about 90% of untreated and mP-hMSCs,
whereas stimulation with TNF-a resulted in the transloca-
tion of NF-kB into the nuclei of TNF-hMSCs and TNF +
mP-hMSCs (Figures 3C and 3D). Preconditioning of hMSCs
with TPCA also did not inhibit nuclear translocation of
NF-kB suggesting the effect of TPCA is significantly attenu-
ated due to its removal from the media. In contrast,
significantly fewer TNF + TPCAmP-hMSCs (about 20% cells)
containedNF-kB in their nuclei (Figure 3D), suggesting that
binding of TPCA to IKK-2 inhibits TNF-a from activating
NF-kB. This suggests that hMSCs could be transiently
controlled for response to TNF-a by loading them with
TPCAmPs.
Secretome from TNF-a-Treated-TPCAmP-hMSCs
Sustainably Inhibits Transwell Migration of Human
Monocytic Cell Line and Human Primary CD14+
Monocytes
Timely inhibition of monocyte migration is necessary to
attenuate irreversible scar formation after MI. To assessStem Cell Reports j Vol. 6 j 926–939 j June 14, 2016 929
Figure 2. Characterization of TPCA-1-Delivering PLGA Microparticles and Internalization in hMSCs
(A) Representative scanning electron microscope image of TPCAmPs showing size, shape, and morphology.
(B) Physicochemical properties of TPCAmPs.
(C) Representative plot of flow cytometry analysis of association of uncoated and PLL-coated DmPs in hMSCs.
(D) Representative confocal images depicting membrane association of uncoated DmPs and cytosolic association of PLL-coated DmPs (red,
DiI-stained cell membrane; green, DmPs; blue, DAPI-stained nucleus).
(E) Profile of TPCA release kinetics from 6 mg of TPCAmPs into PBS at 37C. Error bars represent ±SD.functionality of the inhibited secretome from TNF +
TPCAmP-hMSCs, we investigated transwell migration of a
human monocytic cell line (THP-1) and human primary
CD14+ monocytes (Figure S4A) in response to hMSC secre-
tome (Figures 4A and 4D). Figures 4B and 4D show that the
migration of THP-1 and primary monocytes was dose
dependent. This is evident from the large number of cells
that migrated toward 100% CM, while 1% CM attracted
few cells. CM from days 2, 4, and 6 of TNF-hMSCs
augmented migration of THP-1 cells and primary mono-
cytes across the transwell approximately 4- to 8-fold (Fig-
ure 4B) and approximately 4-fold (Figure 4D) that of CM
from control-hMSCs, respectively. CM from days 2, 4,
and 6 of the soluble TPCA preconditioning regimen was
ineffective in inhibiting migration of cells across the trans-
well, even though less significant reduction was observed
for day 4 and day 6 CM versus CM from TNF-a-stimulated
hMSCs. Conversely, CM from day 2 of TNF + TPCAmP-
hMSCs significantly inhibited migration (3.7-fold and p <
0.01) versus TNF_BmP-hMSCs, and the effect was sustained
through day 4 and day 6 although less significantly (2.5-
fold, p < 0.05 and 1.6-fold, p < 0.01, respectively). A 4- to930 Stem Cell Reports j Vol. 6 j 926–939 j June 14, 20165-fold reduction was observed in the number of primary
monocytes migrated with CM from TNF + TPCAmP-hMSCs
versus CM from TNF_BmP-hMSCs. Direct comparison of
CM from days 2, 4, and 6 reveals that particle-engineered
hMSCs are significantly more efficient in reducing migra-
tion of monocytes than soluble factor preconditioned
hMSCs.
Secretome from TNF-a-Treated-TPCAmP-hMSCs
Inhibits a-SMA Expression and Collagen Production
in Human and Murine Cardiac Fibroblasts
CF differentiate intomyofibroblasts owingmainly to stimu-
lation by TGF-b, but other pro-inflammatory mediators
such as IL-6 and MCP-1 also mediate such pathological
differentiation leading to irreversible scar formation upon
acutemyocardial infarction.Hencewe investigatedwhether
the secretome from TNF + TPCAmP-hMSCs would inhibit
a-smooth muscle actin (a-SMA; myofibroblast specific
marker) expression and collagen production in CMF. Hu-
man (hCF) and mouse (mCF) CF were treated with CM
from different hMSC groups for 96 h at 37C and later
immunostained for a-SMA and imaged. hCF receiving day
Figure 3. Quantitative Analysis of Secretion of Pro-inflammatory Mediators in hMSC Conditioned Medium and NF-kB Nuclear
Translocation in TPCA Preconditioned and Microparticle-Engineered hMSCs on Days 2, 4, and 6
(A) Experimental design for comparing effects of TPCA preconditioning and microparticle engineering regimens in TNF-hMSC.
(B) Fold change in secreted level of RANTES (CCL5), IL-6, and MCP-1 (CCL2) as indicated in hMSCs normalized to the secreted level of
control-hMSC. Data represent the average of triplicates from two different hMSC donors. NS represents non-significance versus TNF-hMSC
and * indicates p < 0.01 versus mP + TNF-hMSC CM.
(C) Representative fluorescence images at 403magnification of hMSCs without microparticles and hMSCs internalized with microparticles
after 30 min of TNF-a (10 ng/ml) stimulation. Blue, DAPI (nucleus); red, NF-kB.
(D) Quantitative analysis of percentage of hMSCs positive for nuclear NF-kB. Each data point is the average of five random fields of view,
and data represent the average of triplicates from three independent experiments from two donor hMSCs. NS represents non-significance
versus TNF-hMSC, * indicates p < 0.01 versus mP + TNF-hMSC CM, and # represents p < 0.01 versus TPCApre + TNF-hMSC CM. Error bars
represent ±SD.2CMfromcontrol-hMSCsor TNF-hMSCswere significantly
positive for a-SMA confirming their CMF phenotype (Fig-
ure 5A). CM fromTPCApre + TNF-hMSCs could only inhibit
a-SMA expression in about 18% of hCF in comparison withCM from control-hMSCs (Figures 5A and 5B). CM from
TNF + mP-hMSCs had a similar effect on a-SMA expression
inhCF in comparisonwithCM fromTNF-hMSCs. However,
day 2 CM from TNF + TPCAmP-hMSC inhibited a-SMAStem Cell Reports j Vol. 6 j 926–939 j June 14, 2016 931
expression in about 80% of hCF versus CM from control-
hMSCs. In addition, CM from particle-engineered hMSCs
reduced the a-SMA expression in hCF 4-fold more than
CM from preconditioned hMSCs. hMSC media alone or
hMSCmediawith TPCA-1 didnot inhibita-SMAexpression
(Figure 5B) in hCF. Next, we sought to examine collagen
deposition by hMSC CM-treated hCF and mCF using Sirius
red staining assay. None of the hMSC CM or hMSC media
or hCF media showed detectable collagen levels when as-
sayed alone for Sirius red staining (Figures S5A and S5B).
On the other hand, when hCF or mCF were treated in
various hMSC media, we could detect significant levels
of collagen (Figures 5C, 5D, 5G, and 5H). Within the
groups, hCF treated in control-hMSC CM, TNF-hMSC CM,
mP-hMSC CM, and TNF + mP-hMSC CM groups had signifi-
cantly higher levels of collagen as quantified by relative
staining intensity in Figures 5D and 5H. hCF treated with
hMSC media or hMSC media + TPCA-1, secreted collagen
at similar levels to control-hMSC CM. Soluble TPCA-1
preconditioned hMSC CM did not significantly inhibit
collagen secretion from hCF, but, hCF in TNF + TPCAmP-
hMSC CM secreted 35% lower amount of collagen com-
pared with control-hMSC CM-treated hCF.
As a first step toward validation in an animal model
in vivo, we chose to analyze whether TPCAmP regulated
hMSC secretome would also affect mouse CF differentia-
tion. The effect of hMSC CM on mCF was similar to hCF
(Figures 5E and 5F) with respect to a-SMA expression.
mCF treated with hMSC media alone or hMSC media
with soluble TPCA-1 had elevated levels of a-SMA expres-
sion (data not shown) in mCF. However, hMSC CM
did not seem to inhibit collagen production of mCF
to the extent of hCF (Figures 5G and 5H). More impor-
tantly, soluble TPCA-1 preconditioned hMSC CM did not
significantly inhibit collagen secretion from mCF. How-
ever, compared with CM from TNF + mP-hMSC, TNF +
TPCAmP-hMSC CM reduced collagen secretion from mCF
by about 24%. This suggests that the inhibited pro-inflam-
matory secretome from particle-engineered hMSCs atten-
uate the adoption of fibrotic phenotype changes in both
hCF and mCF.DISCUSSION
The MSC secretome is being explored in pre-clinical and
clinical trials as one of the primary mediators of cardiovas-
cular repair via immunomodulatory effects (Ranganath
et al., 2012). However, to date, approaches have not met
with success as initially hoped. The immunomodulatory
property of MSCs presents an unpredictable therapeutic
outcome as it is affected by inter-cellular and inter-donor
heterogeneity, the MSC source (Melief et al., 2013; Naf-932 Stem Cell Reports j Vol. 6 j 926–939 j June 14, 2016tali-Shani et al., 2013; Ortiz et al., 2007), and the host
microenvironment (Prockop, 2013). In view of these
heterogeneities, there exists an urgent need to develop a
platform for controlling the MSC secretome post-trans-
plantation. To address this, we subjected hMSCs to a simu-
lated inflammatory microenvironment by TNF-a stimula-
tion (10 ng/ml) and characterized the secretome. It is
important to consider that the levels of TNF-a vary in the
host microenvironment, and thus MSC response cannot
be easily predicted. The pro-inflammatory effect of TNF-a
is generally mediated by NF-kB. In view of this, we investi-
gated whether NF-kB inhibition in TNF-a-stimulated MSCs
could inhibit the pro-inflammatory secretome sufficiently
to suppress outcomes of inflammation. We demonstrate
that the pro-inflammatory phenotype of hMSCs under
an inflammatory stimulus can be transiently inhibited
using intracellular release of a small-molecule inhibitor of
NF-kB (TPCA-1) via microparticles. This in turn is sufficient
to suppress differentiation of CF to CMF.
In hMSCs, TNF-a mediates the upregulation of pro-
inflammatory gene expression and protein secretion via
NF-kB (Carrero et al., 2012; Lee et al., 2010). Of 250 secreted
factors profiled, we found that TNF-hMSCs secreted nine
pro-inflammatory mediators at significantly higher con-
centrations compared with control-hMSCs. These media-
tors, barring RANTES (CCL5), are constitutively secreted,
and TNF-a further augments their secretion levels. Secre-
tion of RANTES, however, seems exclusively to be the result
of TNF-a stimulation since it is not constitutively secreted.
The pro-inflammatory secretome from MSCs is reported
to have deleterious effects in several disease models (Table
S1). Pro-inflammatory mediators such as IL-6 and MCP-1
mediate differentiation of CF to CMF and collagen deposi-
tion, leading to adverse remodeling and heart failure.
MCP-1 attracts circulating monocytes and induces differ-
entiation to M1 macrophages, leading to collagen deposi-
tion and adverse fibrosis in aging hearts (Cieslik et al.,
2014). Macrophages aggravate the inflammatory response
by releasing elevated levels of pro-inflammatory cytokines
including IL-6,MCP-1, IL-8which in turnmediate differen-
tiation of CF to CMF. Hence, therapeutic interventions are
primarily aimed at reducing CMF differentiation thereby
preventing irreversible scar formation and maximizing
viable myocardium. The negative effects of pro-inflamma-
tory mediators under disease settings such as cardiac
fibrosis provided the insight for inhibiting their secreted
levels from hMSCs to maximize the benefits of hMSC-
based therapy.
Initiation and progression of cardiac fibrosis may occur
due to secretion of TNF-a and IL-6 by infused MSCs (Naf-
tali-Shani et al., 2013). Naive BM-MSCs can be pro-inflam-
matory and hence not sufficiently beneficial in improving
ischemic myocardium and might require pretreatment to
Figure 4. Dose-Dependent Transwell Migration of Human Monocytic THP-1 Cells and Human Primary Monocytes for 2 h in Response
to Conditioned Medium from TPCA Preconditioned and Microparticle-Engineered hMSCs
(A) Representative bright-field images of migrated THP-1 cells in the bottom of the wells.
(legend continued on next page)
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maximize efficacy (Eun et al., 2011). For example, infused
TNFR2 and TNFR1/R2 knockout mMSCs (into isolated rat
hearts) after ischemia-reperfusion injury offered either no
benefit or reduced cardioprotection whereas infused
TNFR1 knockout mMSCs provided greater cardioprotec-
tion,measured viamyocardial TNF-a levels and left ventric-
ular diastolic performance compared with WT mMSCs.
This suggests that by controlling TNFR signaling, MSC
phenotype could bemodulated between pro-inflammatory
to anti-inflammatory (Kelly et al., 2010). TNF-a stimulation
(10 ng/ml for 48 hr) also results in a significantly elevated
concentration of pro-inflammatory mediators in the
hMSC secretome (Lee et al., 2010) stimulating migration
of humanmonocytes in vitro that might aggravate inflam-
mation post-MI. Hence, we sought to non-genetically and
transiently inhibit secretion levels of pro-inflammatory
mediators from hMSCs under TNF-a stimulation.
TPCA-1 reversiblybinds to IKKbandprevents it fromphos-
phorylating IkBa for degradation and therebyblocks nuclear
translocation of NF-kB (Kondo et al., 2008). Our results
demonstrate that TPCA-1may inhibit the stimulatory action
of TNF-a on NF-kB. TPCA-1 partially inhibits secretion of
constitutively secreted pro-inflammatory factors such as
IL-6 and MCP-1, which suggests that constitutive secretion
isnot entirelydependentonNF-kBactivation.The reduction
ofRANTES,GRO,andGCP-2 tobasal levelsmay indicate that
NF-kB activation mediates the secretion of these cytokines
upon TNF-a treatment as TPCA-1 abrogates NF-kB activa-
tion. Our cytokine array results confirm that TPCA-1 abro-
gates the effect of TNF-a onproduction of pro-inflammatory
cytokines by hMSCs. In addition, we demonstrated that
TPCA-1 treatment did not inhibit secretion of beneficial
paracrine factors such as growth factors, cytokines, and
anti-inflammatory mediator TSG-6, which when secreted
from lung embolized hMSCs attenuate MI in mice (Lee
et al., 2009).Hence, angiogenic andTSG-6-mediated anti-in-
flammatory properties of hMSCs may not be compromised
upon TPCA-1 treatment. In addition, continuous intra-
cellular TPCA exposure to hMSCs might yield sustained
binding to IKKb, resulting in the inhibition of NF-kB and
overcome reversible inhibitionof IKKb. TPCA-1hasnon-spe-
cific effectsof IKKb inhibitiononmanycell typeswithpoten-
tial undesirable side effects. In addition,MSCsdemonstrate a
‘‘hit and run effect’’ of immune modulation (Levy et al.,
2013) and are cleared from the body within a week post-(B) Quantitative analysis of the number of THP-1 cells migrated into
preconditioned and microparticle-engineered hMSCs. Data represent
(C) Representative bright-field images of migrated primary macropha
(D) Quantitative analysis of the number of primary macrophages mig
TPCA-1 preconditioned and microparticle-engineered hMSCs.
Data represent the average of triplicates from three independent e
whereas * represents p < 0.01 versus T-hMSC CM and $ represents p <
934 Stem Cell Reports j Vol. 6 j 926–939 j June 14, 2016transplantation.Hence it isdesirable to intracellularlydeliver
TPCA-1 into hMSCs at a controlled rate for transient modu-
lation of the pro-inflammatory secretome.
In this study, we developed an engineering platform to
intracellularly deliver TPCA-1 to hMSCs. mPs of 1–2 mm
were internalized following anionic surface modification.
By choosing PLGA polymer with a lactic acid to glycolic
acid ratio of 50:50 and low molecular weight of 10 kDa,
we tailored the release kinetics of TPCA-1 to achieve
a concentration to inhibit IKK2. Upon preconditioning
of hMSCs with soluble TPCA prior to stimulation with
TNF-a, the hMSC secretome was similar to TNF-a stimula-
tion alone (TNF-hMSC) suggesting that IKKb inhibition
may require continued presence of TPCA to prevent NF-kB
activation. The sustained intracellular release of TPCA-1
enabled prolonged inhibition of IKKb and competitively
inhibited TNF-a from activating NF-kB mediated pro-in-
flammatory cytokine secretion. NF-kB signaling in cells is
oscillatory in nature, and gene expression seems to depend
on its dynamics (Nelson et al., 2004). Hence, under contin-
uous TNF-a stimulus, NF-kB activation might be sustained.
However, the effect of intracellular TPCA inhibition in
microparticle-engineered hMSCswasmaintained aftermul-
tiple rounds of TNF-a stimulation suggesting thatmicropar-
ticle-engineered hMSCs are able to control the pro-inflam-
matory phenotype under sustained inflammatory stimulus.
To demonstrate the functional relevance of micropar-
ticle-mediated hMSC secretome regulation, we focused
on cardiac fibrosis. IL-6 (Ma et al., 2012), MCP-1, and other
pro-inflammatory mediators augment monocyte migra-
tion (Lee et al., 2010) and induce differentiation of CF to
CMF, which are the primary scar-forming cells post-MI.
Expectedly, we found that while the elevated levels of
pro-inflammatory mediators in CM from preconditioned
hMSCs are ineffective in inhibiting monocyte migration,
CM fromTNF + TPCAmP-hMSCs effectively inhibited trans-
well migration of THP-1 cells by at least 2- to 3-fold, corre-
sponding to reduced levels of pro-inflammatory mediators
as seen by our secretome analysis.
Control-hMSC CM also induced significant differentia-
tion of CF to CMF demonstrating the presence of pro-
inflammatory mediators secreted by hMSCs as well as
those likely to be present in the culture serum. CM from
control-hMSCs and mP-hMSCs have lower levels of pro-
inflammatory factors (compared with TNF-a-stimulatedthe bottom well in response to 100% CM or 1% CM from TPCA-1
the average of triplicates from three independent experiments.
ges in the bottom of the wells.
rated into the bottom well in response to 100% CM or 1% CM from
xperiments. NS represents non-significance versus TNF-hMSC CM,
0.01 versus mP + TNF-hMSC CM. Error bars represent ±SD.
Figure 5. Analysis of a-SMA Expression and Collagen Deposition of Human and Murine CF in Response to Conditioned Media of
TPCA Preconditioned and Microparticle-Engineered hMSCs
(A) Representative fluorescence images (43) of hCF treated with day 2 CM from each hMSC group (green, a-SMA; blue, DAPI).
(B) Quantitative analysis of the number of a-SMA + hCF treated with day 2 CM from each hMSC group.
(legend continued on next page)
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hMSCs) yet the number of a-SMA+ CMF remained un-
changed when CF were treated with these CM, suggesting
that the secretome may lack anti-inflammatory modula-
tors and growth factors. In addition, treatment with
TPCA-1 alone did not cause a reduction in the number
of a-SMA+ CMF, suggesting that an hMSC-mediated para-
crine function is essential. While TPCA-1 pretreatment of
hMSCs before TNF-a stimulation showed a significant
reduction in CMF numbers, this was greatly enhanced
when TPCA-1 was available intracellularly via the micro-
particles. CM from TNF + TPCAmP-hMSC likely prevented
differentiation of CF to CMF due to the continued intra-
cellular inhibition of IKK-mediated NF-kB activation,
thus preventing the release of an hMSC pro-inflammatory
secretome. Surprisingly, the CMF number was reduced by
over 2-fold, suggesting that TPCA-1 may activate hMSC
pathways that revert the CMF phenotype. We cannot
rule out the possibility that other contributors in the
hMSC secretome that were not profiled might also be
contributing, and their action is facilitated by intracellular
TPCA-1. For instance, in an in vitro 3D model of cardiac
fibrosis under hypoxic conditions, reversal of CMF to
the CF phenotype was shown to be due to reduced MSC
TGF-b levels (Galie and Stegemann, 2014). Our assay
revealed a similar trend in terms of collagen production
from CF. CF treated with CM from control-hMSCs, or
TPCApre + TNF-hMSCs or mP-hMSCs secreted elevated
levels of collagen into the media suggesting that only in-
hibited levels of pro-inflammatory mediators could not be
implicated in the reduction in collagen secretion. The
reduced number of a-SMA+ CMF in CM from TNF +
TPCAmP-hMSCs possibly contributed to the lower secre-
tion level of collagen in the media (Figure 5B). Upon de-
differentiation or lowered a-SMA expression, it is possible
that CMFs lose collagen secretion ability. In regions of MI,
CF switch to the myofibroblast phenotype due to stress
from the infarct scar (Tomasek et al., 2002). High expres-
sion of a-SMA typical in such CMF (Teunissen et al., 2007)
has been implicated for remodeling due to their high
contractility (Santiago et al., 2010). In addition, the
collagen secretion capacity of CMF is very high (Petrov
et al., 2002). Overall, attenuation in the number of
collagen-secreting a-SMA+ CMF could be beneficial in(C) Representative bright-field images of hCF treated with day 2 CM f
(D) Quantitative analysis of relative Sirius red staining intensity from
(E) Representative fluorescence images (103) of mCF treated with da
(F) Quantitative analysis of number of a-SMApos mCF treated with CM
(G) Representative bright-field images of mCF treated with day 2 CM
(H) Quantitative analysis of relative Sirius red staining intensity from
NS represents not significant versus hMSC media + TPCA; NS represen
hMSC media + TPCA; $ indicates p < 0.01 versus TPCApre + TNF-hMSC C
the average of triplicates from three independent experiments from t
936 Stem Cell Reports j Vol. 6 j 926–939 j June 14, 2016preventing pathological remodeling or irreversible scar
formation and allowing cardiac regeneration.
Here we have demonstrated that the pro-inflammatory
hMSC secretome could be inhibited using a microparticle
engineering approach delivering an intracellular NF-kB in-
hibitor, TPCA-1. It is however important to note that the
MSC secretome composition may change depending on
the level of TNF-a encountered in vivo following transplan-
tation. Nevertheless, a similar approach could be beneficial
in inflammatory disease settings such as chronic inflam-
mation and macrophage-mediated atherosclerosis. The
approach of microparticle engineering of an exogenous
cell population by modulating a central regulatory path-
way, may find application in other cell types and pathways
and could provide an attractive strategy for harnessing any
cell secretome for therapy. This approach could also be
potentially employed to modulate the composition of
extracellular vesicles (exosomes) for therapy.EXPERIMENTAL PROCEDURES
Mesenchymal Stromal Cell Culture and
Characterization
HumanMSCs and human andmurineCF culture and characteriza-
tion are described in Supplemental Experimental Procedures.
Stimulation of hMSCs with TNF-a and TPCA-1
Treatment
Primary hMSCs derived from bone marrow of healthy consenting
donorswere cultured in standardmedia andusedatpassagenumber
3–6 (see Supplemental Experimental Procedures). 30,000 cells per
well ina24-well platewerecultured inserum-freeMesenCultXFme-
dia (STEMCELL Technologies) for 24 hr and then treated for 48 hr
with either (1) 0.1% (v/v) DMSO (Sigma) (control-hMSC), or
(2) 10 ng/ml TNF-a (Sigma-Aldrich) (TNF-hMSC), or (3) 10 mM
TPCA-1 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophe-
necarboxamide) (Calbiochem), or (4) 10 mM TPCA-1 and stimu-
latingwith10ng/mlTNF-a (TNF+TPCA-hMSC), followedbycondi-
tioned media (CM) collection. Metabolic activity of cells was
measured using the MTS assay (see Supplemental Information).
Secretome Profiling of Stimulated hMSCs
Quantitative measurement of 250 human cytokines in the stim-
ulated hMSC CM was performed using Quantibody Humanrom each hMSC group.
hCF in response to CM from each hMSC group.
y 2 CM from each hMSC group (green, a-SMA; blue, DAPI).
from each hMSC group.
from each hMSC group.
mCF in response to day 2 CM from each hMSC group.
ts not significant versus TNF-hMSC CM; * indicates p < 0.01 versus
M; # indicates p < 0.01 versus TNF + mP-hMSC CM. All data represent
wo different donor hMSCs. Error bars represent ±SD.
Cytokine Array 5000 (Ray Biotech) according to the manufac-
turer’s instructions. Fluorescence signals at 532 nm from the arrays
were obtained by scanning the slides using an Axon GenePix
4300Amicroarray laser scanner (MolecularDevices). Spot intensity
was quantified into concentration values using standard curves
based on linear regression and analyzed (fold change in concentra-
tion) using GenePix Pro 7 software. See Supplemental Information
for details.
PLGA Microparticle Fabrication, Characterization,
and Engineering of hMSCs
TPCA-1, or Rhodamine 6G dye (Sigma) or DiI dye (Cell Signaling)
were encapsulated in PLGA microparticles using the single-emul-
sion technique. To enhance microparticle uptake and loading
in hMSCs, the surface of PLGA microparticles was modified as
described before (Ankrum et al., 2014b). See Supplemental Infor-
mation for details.
Analysis of Microparticle-hMSC Interaction
DiO-loaded-microparticle internalized hMSCs (DmP-hMSCs) were
trypsinized and analyzed by flow cytometry to characterize the as-
sociation of microparticles with hMSCs. The mean fluorescence of
the gated cell population was quantified. hMSCs with no particles
and blank particles served as controls. DmP internalization was
characterized by confocal microscopy imaging (Zeiss LSM510) of
fixed cells followed by image analysis. Microparticles within the
plane of the nucleus and inside the boundaries of the cell mem-
branewere interpreted to be internalized. Cytotoxicity of TPCAmPs
on hMSCs was measured using the MTS assay as described earlier.
Release Kinetics of TPCA-1 from Microparticles
Invitro releasekinetics ofTPCA-1 fromTPCAmPswasprofiledby sus-
pending 6 mg of TPCA mPs in 1 ml of PBS and loading into a 1.5 3
6 cm polytetrafluoroethylene dialysis membrane (Thermo Fisher
Scientific) with 8–10 kDa molecular weight cut off. The membrane
was then introduced into 20 ml of PBS and incubated at 37C
with shaking. PBS was sampled at specific time points and drug
was extracted using dichloromethane (DCM). Following evapora-
tion of DCM and dissolution of the drug in DMSO, the concen-
tration of TPCA-1 was measured by determining absorbance at
320 nm using a UV-visible spectrophotometer.
Analysis of the Composition and Kinetics of
Preconditioned and Microparticle-Engineered hMSC
Secretome
The experimental procedure is described in Figure 3A. The effect of
TPCA preconditioning or internalized TPCAmPs on TNF-a-treated
hMSC secretome was investigated by performing an ELISA of CM
to quantify MCP-1, IL-6, and RANTES concentrations. See Supple-
mental Information for details.
Statistical Analysis
Single-factor ANOVA was used for multiple pairwise comparisons
with two-factor t test with Bonferroni correction post hoc analysis.
p < 0.01 was considered significant.
See Supplemental Information for additional methods.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, five figures, and one table and can be found with
this article online at http://dx.doi.org/10.1016/j.stemcr.2016.
05.003.
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